prostate cells

[Biochemical and Biophysical Research Communications] Investigators used prostate cancer cell line PC3 and its paclitaxel-resistant counterpart PC3-TxR as the cell model and suggested that lovastatin (LV) might increase the sensitivity of resistant prostate cancer cells to paclitaxel through inhibition of CYP2C8.

[Cell Death Discovery] Scientists discovered an exosomal lncRNA HOXD-AS1 was upregulated in CRPC cell line derived exosomes and serum exosomes from metastatic prostate cancer patients, which correlated with its tissue expression.

[Journal of Surgical Oncology] The authors explored the expression level of miR-214-5p in prostate cancer and made a preliminary study of its molecular mechanism in the development of prostate cancer to provide effective new strategies for the treatment of prostate cancer.

[Prostate] The authors investigated a combination therapy of novel androgen receptor (AR) antagonists and statin, simvastatin, for CRPC and found that a combination of novel AR antagonists and simvastatin could potentially affect CRPC growth through both androgen-dependent and androgen-independent mechanisms.

[Scientific Reports] Researchers characterized and investigated the effects of transient receptor potential melastatin-8 (TRPM8) modulators in prostate cancer aggressiveness disclosing the molecular mechanism underlying their biological activity.

[British Journal of Cancer] Prostate cancer is a global cancer burden and considerable effort has been made through the years to identify biomarkers for the disease. Investigators present the knowledge acquired during the last decade that constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer.